Why did Oncopeptides stock rise on 9 October?
Written after the close on
Oncopeptides +45.15%
Oncopeptides jumped on positive brain-cancer data. Oncopeptides rose very sharply over the last five trading days while the wider Stockholm market was roughly flat, and the sharpest gain came in the latest session, when the market itself also climbed strongly. The likely driver is the company's announcement that its peptide-drug conjugate platform — a way of attaching a toxic payload to a targeting peptide so it reaches tumour cells — successfully crossed the blood-brain barrier in the first glioblastoma patients in its OP-701 (INSULA) study, with tumour drug levels matching preclinical expectations and good tolerability. That is a meaningful signal for a platform whose main challenge is getting drugs into the brain, so the market likely read it as early clinical proof of concept. Watch the investor webcast on 12 October and the next earnings report in early November for follow-up.